EpiCept News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

14.12.16	Research and Markets - Diabetes Diagnostics 2015-2022: Global Strategic Business Report 2016 - Diabetes Diagnostics Innovations & Advancements / Recent Industry Activity / Market Trends, Issues &... (PR Newswire)
20.08.13	EpiCept Announces Reverse Stock Split and Change of Corporate Name to Immune Pharmaceuticals Inc. (PR Newswire)
07.08.13	EpiCept Stockholders Overwhelmingly Approve Final Conditions to Merger with Immune Pharmaceuticals Ltd. (PR Newswire)
07.08.13	EpiCept Stockholders Overwhelmingly Approve Final Conditions to Merger with Immune Pharmaceuticals Ltd. (PR Newswire)
01.08.13	EpiCept Reports Second Quarter 2013 Operating and Financial Results (PR Newswire)
01.08.13	EpiCept Reports Second Quarter 2013 Operating and Financial Results (PR Newswire)
09.01.13	Daniel Teper of Immune Pharmaceuticals to Present at the 6th Annual OneMedForum (Businesswire)
14.11.12	EpiCept Reports Third Quarter 2012 Operating and Financial Results (Businesswire)
12.11.12	EpiCept to Report Third Quarter 2012 Operating and Financial Results on November 14, 2012 (Businesswire)
08.11.12	Immune Pharmaceuticals and EpiCept Corporation Agree to Merge (Businesswire)
25.09.12	EpiCept Corporation Raises $0.8 Million from Immediate Exercise of Re-priced Warrants (Businesswire)
05.09.12	EpiCept Regains Rights to Azixa® from Licensee Myrexis (Businesswire)
31.08.12	EpiCept Amends Loan and Security Agreement (Businesswire)
30.08.12	EpiCept Announces Changes to Its Board of Directors (Businesswire)
21.08.12	EpiCept Announces Resignation of CEO Jack Talley (Businesswire)
08.08.12	EpiCept Reports Second Quarter 2012 Operating and Financial Results (Businesswire)
02.08.12	EpiCept to Report Second Quarter 2012 Operating and Financial Results on August 8, 2012 (Businesswire)
19.06.12	EpiCept Transfers Ceplene Responsibilities in European Union and Sells License Rights to Meda (Businesswire)
12.06.12	EpiCept Corporation to Present at 2012 BIO International Convention (Businesswire)
04.06.12	EpiCept Corporation Receives Scientific Advice from European Medicines Agency for AmiKet™ CIPN Program (Businesswire)
09.05.12	EpiCept Reports First Quarter 2012 Operating and Financial Results (Businesswire)
04.05.12	EpiCept to Report First Quarter 2012 Operating and Financial Results on May 9, 2012 (Businesswire)
30.04.12	EpiCept Makes Required Swedish Regulatory Disclosure (Businesswire)
10.04.12	EpiCept’s AmiKet™ Receives Fast Track Designation from FDA (Businesswire)
04.04.12	EpiCept’s Licensed Compound EP1013 Identified as a New Drug Candidate for Treatment of Late-Stage Viral Hepatitis (Businesswire)
29.03.12	EpiCept to Raise $1.1 Million in Registered Direct Offering (Businesswire)
14.03.12	EpiCept Corporation to Present at the BIO-Europe Spring 2012 Event (Businesswire)
29.02.12	EpiCept Reports Fourth Quarter and Full Year 2011 Operating and Financial Results (Businesswire)
23.02.12	EpiCept Corporation to Report Fourth Quarter and Full Year 2011 Operating and Financial Results on February 29, 2012 (Businesswire)
09.02.12	EpiCept to Raise $2 Million in Registered Direct Offering (Businesswire)
08.02.12	EpiCept to Present at the 14th Annual BIO CEO & Investor Conference (Businesswire)
07.02.12	EpiCept Files for AmiKet™ Fast Track Designation (Businesswire)
24.01.12	EpiCept Corporation Confirms Engagement of SunTrust Robinson Humphrey to Include Evaluation of Potential Sale Transactions (Businesswire)
23.01.12	EpiCept Corporation Receives Finalized FDA Guidance for AmiKet™ Phase III CIPN Program and Regulatory Strategy (Businesswire)
09.01.12	EpiCept Corporation Reduces Exercise Price and Extends Expiration Date of June 2010 Series B Warrants (Businesswire)
09.01.12	EpiCept Corporation Engages SunTrust Robinson Humphrey to Advise on Strategy to Maximize AmiKet™ Potential (Businesswire)
05.01.12	EpiCept to Present at Two Upcoming Industry Conferences (Businesswire)
05.01.12	EpiCept Corporation Appoints Alan W. Dunton, M.D. Non-Executive Chairman of the Board (Businesswire)
23.12.11	EpiCept Corporation Receives FDA Permission to Initiate AmiKet™ Phase III Clinical Development (Businesswire)
21.12.11	EpiCept Provides Update on Ceplene® Manufacturing at Ben Venue Laboratories (Businesswire)
30.11.11	EpiCept to Present at the 22nd Annual Wall Street Institutional Investor Conference (Businesswire)
30.11.11	ElectronVault Creates Next Generation of Energy Storage With Autodesk Software (Businesswire)
22.11.11	EpiCept to Present at the NYSSA Biotech and Specialty Pharma Conference (Businesswire)
22.11.11	Midwest Energy Emissions Corp Stock Symbol Change to MEEC (Businesswire)
08.11.11	T-Mobile Completes Holiday 4G Tablet Portfolio with the Samsung Galaxy Tab™ 7.0 Plus (Businesswire)
08.11.11	EpiCept Corporation Reports Third Quarter 2011 Operating and Financial Results (Businesswire)
18.07.11	EpiCept Corporation Announces Publication in Journal Blood of a New Meta-Analysis Examining Lack of Efficacy of Interleukin-2 as Monotherapy in AML Remission Maintenance (Businesswire)
20.06.11	Adobe Enables Developers to Build Mobile Apps for Android Devices, BlackBerry PlayBook, iPhone and iPad (Businesswire)
20.06.11	EpiCept Corporation Announces Stockholders’ Meeting Results and Adjournment (Businesswire)
28.12.10	EpiCept Announces Initiation of Phase 2B Study of Azixa™ for Front-Line Treatment of Glioblastoma Multiforme by Myrexis (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	30.37	2.88 %	K V
Part Grp Hldg	1’330.00	2.39 %	K V
Roche Hldg G	271.80	1.84 %	K V
Givaudan	3’941.00	1.52 %	K V
Novartis	91.64	0.75 %	K V
Geberit	502.80	-0.59 %	K V
CieFinRichemont	139.55	-0.99 %	K V
Swiss Re	133.25	-1.15 %	K V
Zurich Insur Gr	540.00	-1.32 %	K V
Kuehne+Nagel Int	203.00	-2.12 %	K V

Nachrichten zu EpiCept Corp

Aktien Top/Flop

Meistgelesene Nachrichten